Skip to main content

Advertisement

SpringerLink
Log in

Mechanism-based population modelling for assessment of L-cell function based on total GLP-1 response following an oral glucose tolerance test

  • Published:
Journal of Pharmacokinetics and Pharmacodynamics Aims and scope Submit manuscript

Abstract

GLP-1 is an insulinotropic hormone that synergistically with glucose gives rise to an increased insulin response. Its secretion is increased following a meal and it is thus of interest to describe the secretion of this hormone following an oral glucose tolerance test (OGTT). The aim of this study was to build a mechanism-based population model that describes the time course of total GLP-1 and provides indices for capability of secretion in each subject. The goal was thus to model the secretion of GLP-1, and not its effect on insulin production. Single 75 g doses of glucose were administered orally to a mixed group of subjects ranging from healthy volunteers to patients with type 2 diabetes (T2D). Glucose, insulin, and total GLP-1 concentrations were measured. Prior population data analysis on measurements of glucose and insulin were performed in order to estimate the glucose absorption rate. The individual estimates of absorption rate constants were used in the model for GLP-1 secretion. Estimation of parameters was performed using the FOCE method with interaction implemented in NONMEM VI. The final transit/indirect-response model obtained for GLP-1 production following an OGTT included two stimulation components (fast, slow) for the zero-order production rate. The fast stimulation was estimated to be faster than the glucose absorption rate, supporting the presence of a proximal–distal loop for fast secretion from l-cells. The fast component (st 3  = 8.64·10−5 [mg−1]) was estimated to peak around 25 min after glucose ingestion, whereas the slower component (st 4  = 26.2·10−5 [mg−1]) was estimated to peak around 100 min. Elimination of total GLP-1 was characterised by a first-order loss. The individual values of the early phase GLP-1 secretion parameter (st 3 ) were correlated (r = 0.52) with the AUC(0–60 min.) for GLP-1. A mechanistic population model was successfully developed to describe total GLP-1 concentrations over time observed after an OGTT. The model provides indices related to different mechanisms of subject abilities to secrete GLP-1. The model provides a good basis to study influence of different demographic factors on these components, presented mainly by indices of the fast- and slow phases of GLP-1 response.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Vilsboll T, Agerso H, Krarup T, Holst JJ (2003) Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 88(1):220–224

    Article  PubMed  CAS  Google Scholar 

  2. Brandt A, Katschinski M, Arnold R, Polonsky KS, Goke B, Byrne MM (2001) GLP-1-induced alterations in the glucose-stimulated insulin secretory dose-response curve. Am J Physiol Endocrinol Metab 281(2):E242–E247

    PubMed  CAS  Google Scholar 

  3. Lim GE, Brubaker PL (2006) Glucagon-like peptide 1 secretion by the L-cell. Diabetes 55(Suppl 2):S70–S77

    Article  CAS  Google Scholar 

  4. Meier JJ, Nauck MA, Kranz D, Holst JJ, Deacon CF, Gaeckler D, Schmidt WE, Gallwitz B (2004) Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 53(3):654–662

    Article  PubMed  CAS  Google Scholar 

  5. Rask E, Olsson T, Söderberg S, Holst JJ, Tura A, Pacini G, Ahrén B (2004) Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance. Metabolism 53(5):624–631

    Article  PubMed  CAS  Google Scholar 

  6. Knop FK, Vilsbøll T, Højberg PV, Larsen S, Madsbad S, Vølund A, Holst JJ, Krarup T (2007) Reduced incretin effect in type 2 diabetes. Diabetes 56(8):1951–1959

    Article  PubMed  CAS  Google Scholar 

  7. Dayneka NL, Garg V, Jusko WJ (1993) Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Pharmacodyn 21(4):457–478

    CAS  Google Scholar 

  8. Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, Holst JJ (2001) Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 86(8):3717–3723

    Article  PubMed  CAS  Google Scholar 

  9. Hansen T, Drivsholm T, Urhammer SA, Palacios RT, Vølund A, Borch-Johnsen K, Pedersen O (2007) The BIGTT test. Diabetes Care 30(2):257–262

    Article  PubMed  CAS  Google Scholar 

  10. American Diabetes Association (2004) Diagnosis and classification of diabetes mellitus. Diabetes Care 30(suppl 1):S5–S10

    Google Scholar 

  11. Andersen L, Dinesen B, Jorgensen P, Poulsen F, Roder M (1993) Enzyme immunoassay for intact human insulin in serum or plasma. Clin Chem 39(4):578–582

    PubMed  CAS  Google Scholar 

  12. Orskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ (1994) Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43(4):535–539

    Article  PubMed  CAS  Google Scholar 

  13. Deacon CF, Pridal L, Klarskov L, Olesen M, Holst JJ (1996) Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol Endocrinol Metab 271(3):E458–E464

    CAS  Google Scholar 

  14. Lima JJ, Matsushima N, Kissoon N, Wang J, Sylvester JE, Jusko WJ (2004) Modeling the metabolic effects of terbutaline in [beta]2-adrenergic receptor diplotypes[ast]. Clin Pharmacol Ther 76(1):27–37

    Article  PubMed  CAS  Google Scholar 

  15. Woo S, Pawaskar D, Jusko W (2009) Methods of utilizing baseline values for indirect response models. J Pharmacokinet Pharmacodyn 36(5):381–405

    Article  PubMed  Google Scholar 

  16. Holst JJ (2007) The physiology of glucagon-like peptide 1. Physiol Rev 87(4):1409–1439

    Article  PubMed  CAS  Google Scholar 

  17. Savic R, Jonker D, Kerbusch T, Karlsson M (2007) Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn 34(5):711–726

    Article  PubMed  CAS  Google Scholar 

  18. Silber HE, Frey N, Karlsson MO (2010) An integrated glucose-insulin model to describe oral glucose tolerance test data in healthy volunteers. J Clin Pharmacol 50(3):246–256

    Article  PubMed  CAS  Google Scholar 

  19. Møller J, Overgaard R, Madsen H, Hansen T, Pedersen O, Ingwersen S (2010) Predictive performance for population models using stochastic differential equations applied on data from an oral glucose tolerance test. J Pharmacokinet Pharmacodyn 37(1):85–98

    Article  PubMed  Google Scholar 

  20. Savic R, Karlsson M (2009) Importance of shrinkage in empirical Bayes estimates for diagnostics: problems and solutions. AAPS J 11(3):558–569

    Article  PubMed  Google Scholar 

  21. Rask E, Olsson T, Søderberg S, Johnson O, Seckl J, Holst JJ, Ahrén B (2001) Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men. Diabetes Care 24(9):1640–1645

    Article  PubMed  CAS  Google Scholar 

  22. Dalla Man C, Caumo A, Basu R, Rizza R, Toffolo G, Cobelli C (2004) Minimal model estimation of glucose absorption and insulin sensitivity from oral test: validation with a tracer method. Am J Physiol Endocrinol Metab 287(4):E637–E643

    Article  PubMed  CAS  Google Scholar 

  23. Thomaseth K, Pavan A, Berria R, Glass L, DeFronzo R, Gastaldelli A (2008) Model-based assessment of insulin sensitivity of glucose disposal and endogenous glucose production from double-tracer oral glucose tolerance test. Comput Methods Prog Biomed 89(2):132–140

    Article  Google Scholar 

  24. Orskov C, Wettergren A, Holst JJ (1993) Biological effects and metabolic rates of glucagonlike peptide-1 7–36 amide and glucagonlike peptide-1 7–37 in healthy subjects are indistinguishable. Diabetes 42(5):658–661

    Article  PubMed  CAS  Google Scholar 

  25. Kreymann B, Ghatei MA, Williams G, Bloom SR (1987) Glucagon-like peptide-1 7–36: a physiological incretin in man. Lancet 330(8571):1300–1304

    Article  Google Scholar 

Download references

Acknowledgments

This study was partly supported by NIH Grant GM 57980 for WJJ and WG.

Author information

Authors and Affiliations

  1. Quantitative Clinical Pharmacology, Novo Nordisk A/S, Søborg, Denmark

    Jonas B. Møller, Rune V. Overgaard & Steen H. Ingwersen

  2. Department of Informatics and Mathematical Modelling, Technical University of Denmark, Lyngby, Denmark

    Henrik Madsen

  3. Department of Pharmaceutical Sciences, State University of New York at Buffalo, Buffalo, NY, USA

    William J. Jusko & Wei Gao

  4. Hagedorn Research Institute, Gentofte, Denmark

    Torben Hansen & Oluf Pedersen

  5. Department of Medical Physiology, Panum Institute, University of Copenhagen, Copenhagen, Denmark

    Jens J. Holst

Authors
  1. Jonas B. Møller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. William J. Jusko
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wei Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Torben Hansen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Oluf Pedersen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jens J. Holst
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Rune V. Overgaard
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Henrik Madsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Steen H. Ingwersen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jonas B. Møller.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Møller, J.B., Jusko, W.J., Gao, W. et al. Mechanism-based population modelling for assessment of L-cell function based on total GLP-1 response following an oral glucose tolerance test. J Pharmacokinet Pharmacodyn 38, 713–725 (2011). https://doi.org/10.1007/s10928-011-9216-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10928-011-9216-2

Keywords

Search

Navigation